本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
QINGDAO, China, Feb. 3, 2026 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the launch of the an exploratory patient support program and a strategic cooperation with Nanning Duoling Research Institute. Adopting an integrated model of "Traditional Chinese Medicine (TCM) practice + modern medical technology", certain medical resources will be coordinated and integrated to provide free in-hospital treatment plans for up to 10,000 eligible patients within participating medical institutions. The patient support program directly addresses the urgent needs of cancer patients and reconstructs the standards of medical accessibility through "global resource integration + zero-cost access". Akso Health plans to open its global medical network, connecting the radiation oncology centers under its planning and construction withtargeted drugs andremote consultation teams. Pursuant to a strategic cooperation framework agreement, Nanning Duoling will provide its exclusive cancer diagnosis and treatment technologies, reagent and consumable supply system, professional laboratory testing capabilities, and an exclusive team composed of experts in the field of cancer diagnosis and treatment. The two parties will work together to build a closed-loop model of "global resource connection + local technology landing + full-cycle patient service", and the core breakthrough of this model is "zero-cost full-chain coverage", which directly addresses the core pain points of high medical costs, difficulty in accessing medical care, and uneven treatment effects faced by more than 20 million new cancer patients worldwide and 4.06 million new annual cases in China. This program is an important initiative for the Company to continuously explore how to improve the actual accessibility of specific medical support resources within the compliant medical system. It aims to explore a potential framework for coordinating and integrating third-party medical resources through licensed and compliant medical institutions to help patients obtain specific medical services. Any services that may be provided under the program will be fully offered by independent medical institutions and licensed medical professionals, rather than directly by the Company. Specific arrangements, if any, must meet conditions such as patient eligibility, institutional qualifications, applicable regulatory requirements, and funding accessibility. The Company believes that the launch of this exploratory global patient support initiative may allow for further assessment of scalability and feasibility, subject to ongoing review. Akso Health emphasized that the long-term value of healthcare innovation lies not only in research and development, but also in the ability to responsibly evaluate implementation models within real-world medical systems. Through the integration of institutional experience, research collaboration, and system-level coordination, the Company continues to explore ways to support sustainable and compliant healthcare accessibility. Yilin (Linda) Wang, Chief Executive Officer of Akso Health Group, stated,"We believe it is important to responsibly explore ways to support broader access to healthcare resources, while fully respecting regulatory boundaries and the essential role of licensed medical professionals. This initiative represents an early-stage effort, and we intend to proceed cautiously and deliberately." The initiative is designed to assess potential approaches to enhancing healthcare accessibility through structured coordination and support mechanisms, while maintaining a clear separation between the Company's corporate activities and the delivery of regulated medical services. Participation, if available, would be offered on a limited and phased basis and does not involve any commercial promotion of medical products or therapies. Patients or family members interested in participating in the free treatment support program may register or make inquiries via the following email address: ir@ahgtop.com. All applications will be collected centrally, and eligible applicants will be contacted in due course. About Akso Health Group Akso Health Group (NASDAQ: AHG), formerly known as Xiaobai Maimai Inc., upon exploration of e-commerce platforms, the Company started exploring the healthcare equipment and product trading and related healthcare services business. Currently, the Company specializes in the sales of medical devices in China and in the United States and also conducts certain radiotherapy oncology center-related operations in the United States. In March 2024, the Company indirectly acquired equity interests in Tianjin Deyihui Internet Hospital and Tianjin Deyihui Clinic Co., Ltd., which provide online medical consultations for initial diagnosis, follow-up consultations, and management of chronic diseases. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "potential," "continue," "ongoing," "targets," "guidance" and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but not limited to the following: risks related to our ability to obtain equipment, technology, license and talents at satisfactory terms to grow the medical equipment business and/or to start the planned healthcare business, if at all; risks related to the Company's ability to adapt and make the necessary adjustments to compete and operate effectively; risks related to decisions or changes in governmental policies in the healthcare segment; risks related to increased competition and the development of new competing services; the risk that we may be unable to develop or achieve commercial success for our medical and healthcare services in a timely manner, or at all; risks related to regulatory requirements or enforcement in relevant jurisdiction and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to successfully integrate and derive benefits from any technologies that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; and risks related to uncertainties in regulatory oversight of healthcare-related services, limitations on the promotion or commercialization of unapproved medical products; risks that any evaluated service models may not progress beyond exploratory stages; risks on healthcare service arrangements, limitations on the promotion or delivery of medical-related services, uncertainties regarding third-party medical providers, and the risk that contemplated collaborations may not progress beyond preliminary or framework stages. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this announcement is current as of the date of this announcement, and the Company does not undertake any obligation to update such information, except as required under applicable law. For more information, please visit http://www.ahgtop.com/en/index.html For investor inquiries, please contact: Akso Health GroupInvestor RelationsEmail: ir@ahgtop.com Website: www.ahgtop.com
Didcom is recognized for driving customer acquisition and operational transformation through engineering excellence and intelligent mobility solutions. SAN ANTONIO, Feb. 3, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Didcom has been awarded the 2025 Mexican Customer Value Leadership Recognition in the Intelligent Mobility & Connected Truck Telematics sector for its outstanding achievements in engineering innovation, ecosystem partnerships, and customer-focused operational transformation. This recognition highlights Didcom's consistent leadership in delivering cost-efficient, reliable, and scalable telematics solutions that build lasting operational trust in a rapidly evolving mobility landscape. Guided by a long-term growth strategy centered on AI-powered analytics, Edge Intelligence, and real-time data capabilities, Didcom has shown its ability to adapt and lead in an increasingly intelligent and connected mobility environment. The company's strategic agility and sustained investment in proprietary engineering, modular sensor-to-cloud architecture, and OEM-aligned integration have enabled it to scale effectively across Mexico while strengthening its presence in broader North American and international markets. "Didcom's customer acquisition model thrives on long-standing partnerships, strong engineering alignment with OEMs, and the ability to deploy scalable solutions that adapt to evolving fleet needs," states Benson Augustine, Program Manager for Aftermarket & Digital Retail, Mobility, at Frost & Sullivan. Innovation is central to Didcom's approach. Its comprehensive platform integrates OEM-embedded connectivity, aftermarket versatility, and engineering-driven integration within interoperable ecosystems that support traditional, hybrid, and electric fleets. By consolidating real-time operational data—including vehicle health, energy usage, safety signals, and driver behavior—into a unified intelligence-ready environment, Didcom enables fleets to move from manual oversight to predictive, automated, and AI-assisted operations. This approach improves efficiency, enhances safety outcomes, and ensures continuity and reliability across diverse operating conditions. Didcom's unwavering commitment to customer experience further strengthens its position as a customer value leader. By prioritizing reliability, continuity, and operational trust, the company delivers a strong ownership experience supported by localized engineering expertise and responsive partner ecosystems. Its modular architecture and cost-efficient pricing strategy enable fleets and manufacturers to achieve measurable economic impact through fuel and energy optimization, predictive maintenance, and intelligent operational decision-making. "This Customer Value Leadership recognition by Frost & Sullivan confirms what has guided Didcom since day one: engineering must translate into real operational value for our customers. We don't build technology for the sake of innovation—we design solutions that fleets can trust, scale, and operate with confidence. This recognition reinforces our responsibility to continuously strengthen reliability, execution, and intelligent mobility built from the ground up," said Eng. Yojanan Cornejo Chait, Didcom CEO & Founder. Frost & Sullivan commends Didcom for setting a high standard in competitive strategy, execution, and market responsiveness. The company's vision, engineering excellence, and ecosystem-led innovation are shaping the future of intelligent mobility and connected truck telematics while delivering tangible results at scale. Each year, Frost & Sullivan presents the Customer Value Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in customer satisfaction, operational performance, and competitive positioning. It recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices Recognition Frost & Sullivan's Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.Contact us: Start the discussion. ContactCamila Tinajerocamila.tinajero@frost.com About Didcom Didcom is a Mexican company specializing in applied engineering, smart hardware, embedded systems, telematics, and advanced solutions for mobility and fleet operations. With over 17 years of experience, Didcom drives operational efficiency through high-impact technologies focused on safety, productivity, and data-driven decision-making. Visit Didcom at didcom.com.mx ContactFernando GarcíaMarketing Managerfernando.garcia@didcom.com.mx
Showcasing 'Control Tower 2.0': Incorporating patented AIoT technology for hyper-precise visibility and intelligence across the entire logistics process. Proven Technology: Secures third investment round (Series B-2) within just four years of establishment. Confidence in Innovation: Offering immediate on-site PoC opportunities for attendees to experience logistics transformation. SEOUL, South Korea, Feb. 3, 2026 /PRNewswire/ -- Willog (https://willog.io/en), a leading provider of AIoT-based supply chain intelligence solutions, announced today that it will participate in Manifest 2026, the world's largest logistics tech conference held in Las Vegas from February 9 to 11. At the event, Willog will unveil its next-generation supply chain management solution, 'Control Tower 2.0,' for the first time. Manifest 2026, Accelerating Global Expansion with Series B-2 Funding Alongside this product launch, Willog announced the successful closure of its Series B-2 funding round. This marks the company's third successful investment round in just four years, following Series A in 2021 and Series B in 2023. This achievement serves as a significant validation of Willog's sustained growth and differentiated technological capabilities in the competitive global market. Introducing Control Tower 2.0: The Evolution of Visibility The 'Control Tower 2.0,' debuting at Manifest 2026, is an integrated management solution that covers the entire supply chain—from warehouse storage to domestic and international transport. Its core strength lies in providing seamless, end-to-end visibility based on high-precision data collected via Willog's proprietary, patented IoT sensor devices. Going beyond simple location tracking, Control Tower 2.0 delivers true 'Logistics Intelligence.' The solution utilizes advanced algorithms to precisely analyze critical environmental variables collected by sensors, including temperature, humidity, shock, tilt, and light. By predicting potential issues in advance and analyzing historical data to prevent future risks, Willog provides enterprises with actionable results, supporting cost reduction and strategic optimization. Experience-Centric Booth & Live Demos Willog has designed its booth at Manifest 2026 not just as a display, but as an experience-centric space where visitors can tangibly feel the solution's value. Attendees can get hands-on with the physical lineup of Willog's diverse IoT sensor devices. Furthermore, the experience zone will feature vivid live demos showing exactly how Control Tower 2.0 visualizes real-world data and derives meaningful insights. Exclusive On-Site Offer: Free PoC Program A key highlight of Willog's presence is the on-site Proof of Concept (PoC) program. Willog is offering a complimentary opportunity for qualified booth visitors to deploy its IoT devices and Control Tower solution directly into their actual logistics operations. This initiative allows potential clients to verify technological effectiveness in their specific environments and experience data-driven logistics innovation with zero financial burden. This Series B-2 investment serves as market validation of Willog's vision for the digital transformation of supply chains, said a spokesperson for Willog. The PoC opportunity we are offering at Manifest 2026 is an expression of Willog's strong confidence in its technology. It will serve as a moment for global customers to truly experience logistics innovation through practical intelligence. For more information on Willog's participation in Manifest 2026 and to schedule a pre-meeting, please visit the official event page at https://event.willog.io/. About Willog Willog is a premier AIoT-based supply chain solution provider that goes beyond simple location tracking to ensure transparency and predictability across the entire logistics process. Utilizing proprietary, patented IoT devices, Willog accurately collects not only real-time location data but also critical environmental metrics affecting cargo integrity, including temperature, humidity, shock, tilt, and light exposure. This collected data is analyzed using proprietary algorithms specialized for specific logistics domains, allowing the system to predict potential disruptions and proactively prevent risks based on historical patterns. This enables real-time comprehensive monitoring of all logistics assets, including moving cargo and goods stored within facilities. By forecasting and managing every stage of the supply chain, Willog empowers enterprises to optimize their logistics strategies while minimizing costs and risks. Recognized for its technological prowess, Willog continues its rapid growth trajectory, having successfully secured Series B-2 funding recently, following Series A in 2021 and Series B in 2023. The company was also honored with a Presidential Citation at the '2025 Venture Business Promotion Merit' awards in South Korea. Currently, Willog is accelerating its global expansion through its U.S. subsidiary.
Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment of USD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly differentiated small molecule KIF18A inhibitor in development for chromosomally unstable solid tumors designed using Insilico's generative AI engine. CAMBRIDGE, Mass., Feb. 3, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage, generative artificial intelligence (AI)-driven biotechnology company, today announced that it has received USD 5 million from Menarini Group ("Menarini") as an additional milestone payment, following the completion of first-in-patient dosing in a Phase 1 study of MEN2501, which was licensed to Menarini in January 2025. MEN2501 (previously known as ISM9682) is a highly differentiated small molecule inhibitor of kinesin KIF18A motor protein with potent activity in cancers with chromosome instability. As part of a strategic collaboration to accelerate the development and delivery of transformative cancer therapies, the asset was subsequently licensed to Stemline Therapeutics, Inc. ("Stemline"), a wholly owned subsidiary of the Menarini Group, with the combined value of the agreements exceeding USD 550 million. Pursuant to the partnership, both parties actively advanced the program transition and subsequent development activities. Following IND approval for this program, Insilico received the first development and regulatory milestone payment of USD 3 million in July 2025. "The program rapidly advanced into a Phase I clinical trial and successfully completed first patient dosing, fully demonstrating Menarini and Stemline's exceptional agility and clinical expertise," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "This milestone shows our shared commitment to delivering innovative therapies for cancer treatment. We are proud to further strengthen our partnership and encouraged to see AI-discovered drug candidates reaching such a critical stage, bringing us closer to providing novel treatment options for patients worldwide." "Getting the first patient dosed in our MEN2501 Phase 1 study is a meaningful milestone that underscores how quickly promising science can move forward through focused clinical execution," said Elcin Barker Ergun, CEO of the Menarini Group. "We value our partnership with Insilico as we translate AI-enabled discovery into clinical programs, with the goal of bringing new, transformational treatment options to patients facing aggressive cancers." The collaboration between Insilico and Menarini has continued to expand since its inception. Prior to MEN2501, in January 2024, Insilico announced that it entered into an exclusive global license collaboration with Menarini for MEN2312, a novel KAT6 inhibitor for breast cancer and other oncology indications, with the combined value of the agreements exceeding USD 500 million. The MEN2312 program has progressed smoothly into clinical development, and Insilico has received early development milestone payments. In addition to the collaboration pipelines, Insilico has extensive experience in AI-driven oncology, drug discovery and development. The company has established a robust oncology pipeline that targets multiple cancer indications, leveraging both moderately novel and well-established mechanisms. Among its most promising assets, the potential best-in-class pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412 are both undergoing global, multicenter Phase I clinical trials. Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program. About Insilico Medicine Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com
NEW YORK, Feb. 3, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer Ashley Mastronardi delivers the pre-market update on February 3rd Stocks are mixed as investors track a heavy week of corporate earnings — including reports from NYSE‑listed Pfizer, Eaton, Uber, and Eli Lilly — while labor data is disrupted by the postponement of Friday's January Jobs Report due to the partial government shutdown. With government data delayed, market attention is shifting to private‑sector indicators and corporate outlooks to gauge the strength of the U.S. economy. NYSE-listed AstraZeneca scored a winning debut on the NYSE during Monday's session, climbing 0.7%. The firm began trading on the exchange, marking the largest company transfer by market capitalization in NYSE history. Opening BellOracle Corporation (NYSE: ORCL) rings the Opening Bell Closing BellTyler Technologies (NYSE: TYL) celebrates its 60th birthday Click here to check out Industry's time at the NYSE
SEATTLE, Feb. 3, 2026 /PRNewswire/ -- Tineco today shared its design-led vision for modern floor care, highlighting how thoughtful engineering and human-centered thinking continue to shape more intuitive, effortless cleaning experiences. The approach reflects a broader evolution in how floor care fits naturally into everyday living. How Tineco Makes Everyday Living Feel Effortless In today's homes, innovation is no longer judged by how advanced it sounds, but by how seamlessly it integrates into daily life. For Tineco, smart living has never been about adding complexity. Instead, it begins with thoughtful design—designed to reduce effort, remove decision-making, and create cleaning experiences that simply feel right. Across its product portfolio, Tineco has built a reputation not only for performance, but for a design philosophy rooted in real consumer behavior. Each design choice is guided by one principle: make everyday living feel effortless. Intelligence that works quietly in the background One of the most defining examples of this philosophy is Tineco's iLoop smart sensor technology. Rather than asking users to adjust modes, settings, or power levels, iLoop continuously senses real-time conditions and automatically adapts key performance elements—such as water flow, suction power, and brush movement—based on actual cleaning needs. This intelligent balance allows products to deliver optimal performance without unnecessary resource use. By adjusting only when needed, iLoop helps extend runtime, reduce water replacement frequency, and maintain consistent cleaning results from start to finish. More importantly, it removes the mental load from the user. The product makes the decisions, so users don't have to. Developed from a consumer-first perspective, iLoop has become a core design foundation across Tineco's floor washers, vacuum cleaners, and carpet cleaning solutions—reflecting a brand belief that true intelligence should feel invisible, intuitive, and reassuring. Designed around how people actually move Effortless living is not only about intelligence—it's also about how a product feels in motion. From the early S3 series, Tineco began redefining what a floor washer could be, and with each generation, the brand has continued to refine the physical interaction between user and machine through extensive user testing and long-term feedback. Over time, Tineco re-engineered key structural elements, including repositioning water tanks from the front of the body to the rear and eventually integrating them closer to the top of the brush head. These changes were driven by real-world usage studies, aimed at improving balance, reducing wrist strain, and creating a more natural cleaning posture. Building on this foundation, later generations introduced assisted movement technologies that respond to user motion, subtly supporting both forward and backward movement. This approach allows the product to glide smoothly with minimal effort, creating a lighter, more controlled experience—especially during extended cleaning sessions. Rethinking everyday categories through design Tineco's design thinking also extends to reimagining product categories that have traditionally been associated with heavy, infrequent use. In carpet care, conventional cleaners are often bulky and physically demanding, leading many households to use them only once or twice a year despite the investment. By rethinking weight distribution and integrating clean and dirty water into a single, top-mounted tank positioned closer to the ground, Tineco redesigned the carpet cleaning experience to feel more balanced and approachable. Combined with assisted movement that helps guide the product across carpets, this design reduces physical strain and encourages more frequent, practical use. This reimagined approach to carpet care is exemplified by the Carpet One Cruiser, which was recognized by TIME as one of its Best Inventions of 2025—an acknowledgment of how thoughtful design can transform everyday categories and make powerful tools genuinely accessible. When products belong naturally in the home As a brand that helped define the modern floor washer category, Tineco also believes that performance should coexist with living spaces—not compete with them. Over time, consumer feedback revealed a shift in expectations: cleaning appliances were no longer meant to be hidden away, but to exist naturally within modern interiors. Beginning with the S9 Series, Tineco elevated material quality, refined proportions, and simplified its visual language. The result is a new generation of floor washers designed to sit comfortably within living rooms or bedrooms, complementing different interior styles while reinforcing a sense of pride and trust in ownership. Designing for life, not just cleaning For Tineco, smart design is not about chasing features—it's about understanding how people live, move, and feel in their homes. By combining intelligent sensing, ergonomic engineering, and refined aesthetics, the brand continues to shape cleaning experiences that feel intuitive, balanced, and quietly powerful. Because when design truly works, it doesn't ask for attention—it simply makes life easier. About TinecoTineco ("tin-co") was founded in 1998 with its first product launch as a vacuum cleaner and, in 2019, pioneered the first-ever smart vacuum. Today, the brand has evolved into a global leader in intelligent appliances spanning floor care, kitchen, and personal care categories. With a growing user base of over 23 million households and availability in approximately 30 countries worldwide, Tineco remains committed to its brand vision of making life easier through smart technology and continuous innovation. For more information, visit us.tineco.com.
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
